1

Attendee Bios

Collaboration + Innovation = InspirationSAS | Cary, NC

November 6 – 7, 2014

2

Dr. Joel W. Beetsch, PhDVice President, Patient Advocacy, Corporate Affairs Celgene

Joel Beetsch currently holds the position of Vice President of Patient Advocacy within the Celgene Corporate Affairs Department. In this position, Dr. Beetsch leads the global development and execution of a coordinated patient-focused Advocacy strategy working with multiple patient, provider, payer, and policy organizations to foster safe and effective solutions to healthcare challenges. These efforts drive the assurance that patient access to healthcare solutions and medical innovation and are valued and advanced.

During his 15 year tenure in the biopharmaceutical industry, Dr. Beetsch has held several Medical and Corporate Affairs positions. Joel has professional interests in patient-focused care coordination, health policy, and the use of health information technology.

Joel earned his Doctorate in Neurobiology/Biochemistry from the Boonshoft School of Medicine at Wright State University. Following his doctoral work, Dr. Beetsch was further trained in cellular physiology at the Washington University School of Medicine in St. Louis.

Mr. Riccardo BragliaGroup CEO Helsinn Healthcare SA

Riccardo Braglia is an entrepreneur, HELSINN GROUP’s Chief Executive Officer, Managing Director and Member of HELSINN HOLDING’s Board of Directors, Switzerland and Executive Committee for HELSINN GROUP’s strategic management. He is the CEO and Managing Director of Helsinn Healthcare, Switzerland as well as of Helsinn Advanced Synthesis, Switzerland. He is Member of Helsinn Birex Pharmaceuticals’ Board of Directors, Ireland and Chairman of Helsinn Therapeutics’ Board of Directors, USA.

Riccardo Braglia is also Board Member of Thorne Research, Greenwich CT/USA and WellnessFX.com as well as Member of Management Committee of Chamber of Commerce & Industry of Canton Ticino, Lugano/Switzerland, Board Member of American School in Switzerland, Montagnola and Chairman of WS Fashion Holding Switzerland, Lugano.

Riccardo Braglia is an entrepreneur; he won the “2011 Best Entrepreneur of the Year in Italian-speaking Switzerland Award” awarded by Swiss Venture Club as well the “Ernst & Young Award for the best Swiss Entrepreneur of the Year 2012 in the High Tech/Life Sciences category”. He represented Switzerland at the “Ernst & Young World Entrepreneur of the Year 2013 Award”.

Riccardo Braglia holds a degree in Business Economics with specialization in Industrial Management from Luigi Bocconi University, Milan.

2 3

Mr. David R. BrennanChairman’s Advisory Council CEO Roundtable on Cancer

David Brennan has 38 years of experience in the pharmaceutical industry. Most recently, he was Chief Executive Officer of AstraZeneca PLC from 2006 to June 2012. He previously served as the company’s EVP of North America (2001-2006) and the SVP of Commercialization and Portfolio Management (1999-2001).

While CEO, he led a team of nine global executives, 65,000 employees and over $30 billion in sales. Brennan was a member of the AstraZeneca PLC Board of Directors from 2005 to 2012.

Prior to his work at AstraZeneca, Brennan was an Executive Board member and Chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) and an Executive Board Member of the European Federation of Pharmaceuticals Industries and Associations (EFPIA). He was President and Executive Board member of the International Federation of Pharmaceuticals Manufacturers and Associations (IFPMA); a member and Steering Committee participant of the European Round Table of Industrialists (ERT); and a participant and member of the International Business Council for the World Economic Forum (WEF). He was also an Advisory Board member at Tsinghua University in Beijing, as well as Board Chair for the PA Region American Heart Association.

Brennan currently serves on the boards of the CEO Roundtable on Cancer Chairman’s Advisory Council, The Gettysburg College Board of Trustees, Alexion Pharmaceuticals, Insmed Pharmaceuticals and Innocoll Pharmaceuticals.

Dr. Bruce A. Chabner, MDDirector of Clinical Research, Cancer Center Massachusetts General Hospital

For the past 45 years I have devoted myself to a career in cancer research and drug development. I directed the Drug Development Program and the clinical trials efforts of the National Cancer Institute, as Director of the Division of Cancer Treatment, for 14 years (1981-1995), and have designed, participated in, and reported clinical and pharmacological studies of new agents, including maytansine, folate analogues, paclitaxel, fludarabine, and Yondelis. Seventeen years ago I moved to Harvard Medical School and the Massachusetts General Hospital, where I was Chief of the Division of Hematology/Oncology from 1995-2006 and Clinical Director of the MGH Cancer Center from 1995-2010. For the past 11 years I have had a leadership role in the Dana

Farber Harvard Cancer Center, as Associate Director of Clinical Sciences from 2000-2011, and C-director of the Translational Pharmacology and Experimental Therapeutics Program, 2000-present. I am currently the Director of Clinical Research at the MGH Cancer Center. I author the standard textbook on the pharmacology of anticancer drugs (The Principles and Practice of Cancer Chemotherapy and Biotherapy) now in its 5th edition, and co-edit the standard medical textbook on pharmacology (Goodman and Gilman’s Pharmacological Basis of Therapeutics). Many of the drugs I have studied, most particularly fludarabine, cytosine arabinoside, and antifolates, remain standard agents, but my interests have turned toward the strategic and regulatory issues related to development of targeted drugs. Throughout this career I have remained active as a clinician, teacher, and mentor of academic physician-investigators in the cancer field.

4

Mr. Michael CraggDeputy Director of Athletics / Operations Duke University

Mike Cragg, a 26-year veteran of sports administration, helps lead the Duke athletics department in his role as Deputy Director of Athletics/Operations. During his time at Duke, Cragg has been an integral leader and strategic planner within virtually every area and aspect of the athletics department and thus his role as Duke’s chief operations officer. Duke annually ranks among the most successful programs both on and off the fields of intercollegiate competition with top graduation rates and Top 20 annual NACDA Directors’ Cup finishes. At Duke since 1987, his chief responsibilities are to oversee the administration, operations and fundraising for Duke’s highly successful men’s basketball program. The senior administrator of the

program since 2000, he helped found the Duke Basketball Legacy Fund and has been responsible for helping to raise over $65 million, while also completing the program’s naming gift endowment program with over $25 million in philanthropic gifts.

Dr. Gregory Curt, MDExecutive Director, Scientific & Medical External Relations AstraZeneca Pharmaceuticals

Dr. Curt received his MD with distinction in research from the University of Rochester School of Medicine in 1977. He subsequently completed his training in internal medicine as an intern and resident at the New England Deaconess Hospital and as a Research Fellow at the Peter Bent Brigham Hospital, Harvard Medical School.

Dr. Curt’s training in Medical Oncology was completed in the NCI’s Medicine Branch from 1980-1983, following which he led the intramural NCI Phase I Cancer Drug Development Program. His basic research explored the molecular mechanisms of drug resistance in cancer cells. Dr. Curt served as deputy director of NCI’s Division

of Cancer Treatment from 1985-1988, overseeing the Division’s extramural research grant and contract portfolios. He was appointed Clinical Director of the National Cancer Institute in 1989. He was awarded the Outstanding Service Medal of the US Public Health Service in 1992.

Dr. Curt joined AstraZeneca Oncology in 2002 as Senior Director and Alliance Manager for the National Institutes of Health. Under his leadership, AstraZeneca has forged important new partnerships with NCI in cancer drug development in cancer prevention and treatment including novel-novel combinations. . He has served as US Medical Science Lead for Strategic Alliances, Physician Lead for the US Oncology Phase 1 Team, and US Group Director for late stage drug strategy in Global Medicines Development. He is now Executive Director for External Relations in US Medical Affairs.

4 5

Mr. Habib DableExecutive Vice President, Global Head, Specialty Medicine Bayer HealthCare Pharmaceuticals Inc.

Mr. Habib Dable is the Executive Vice President of Specialty Medicine at Bayer HealthCare Pharmaceuticals. He is responsible for global strategic marketing and commercial operations for its specialty segment across four distinct therapeutic areas in hematology, neurology, oncology and ophthalmology. In his 20-year career with Bayer, Mr. Dable has held senior positions in the U.S., Canada, Latin America, Asia Pacific and Japan focusing on strategic planning, product development and sales management.

Dr. H. Shelton Earp, MDDirector UNC Cancer Center

Shelton Earp is the Lineberger Professor of Cancer Research, Director of UNC Cancer Care and former Director of the UNC Lineberger Comprehensive Cancer . In these roles, he has helped develop basic, clinical and public health research and cancer care at one of the country’s premier public universities and academic medical centers. He serves as Principal Investigator of the UNC Breast Cancer SPORE and his laboratory conducts fundamental and translational research in breast and prostate cancer as well as childhood leukemia. His group has discovered and studied genes involved in a range of cancers ,published over 160 biomedical-research articles and been continuously funded by NIH for over 35 years. He is currently collaborating

with the UNC Chemical Biology Center in the Eshelman School of Pharmacy to develop a new, first-inclassdrug targeting one of the cancer genes discovered in his lab.

Dr. Earp has received UNC School of Medicine teaching awards and chaired national review committees for the American Cancer Society and the National Cancer Institute. He has served as President of the American Association of Cancer Institutes, on the NCI Board of Scientific Advisors, and on the advisory boards of ten university cancer centers. His lab is supported by NIH grants, the Breast SPORE, the Melanoma Research Foundation, and the Breast Cancer Research Foundation.

Dr. Antonio “Tito” Fojo, MD, PhDSenior Investigator, Genitourinary Malignancies Branch National Cancer Institute

Dr. Fojo was born in Havana, Cuba, moved to the United States with his family in 1960, and became a U.S. citizen in 1970. He received his MD and PhD from the University of Miami. He completed 3 years of training in internal medicine at Washington University/Barnes Hospital in St. Louis, and after a year as chief resident came to the NCI as a clinical associate in the Medicine Branch. After 3 years with Drs. Ira Pastan and Michael Gottesman, he assumed the position of Senior Investigator in the intramural program of the NCI, a position he has held for 27 years. Eight years ago he became Director of the Medical Oncology Fellowship Program one of the

6

largest in the United States. His research interest include: (1) drug resistance - understanding basic mechanisms of resistance and how to improve therapies by overcoming such mechanisms; (2) microtubule-targeting agents - how they work and how to better use them; (3) the conduct of clinical trials especially as they relate to drug approvals and drug costs; (4) the biology and molecular biology of adrenocortical cancers and pheochomocytomas; and (5) novel ways to analyze clinical data to better understand outcomes and to mine such data for basic insights.

Dr. James H. Goodnight, PhDCEO SAS Institute

Since he co-founded SAS in 1976, Jim Goodnight has served as the company’s Chief Executive Officer. The worldwide leader in business analytics, SAS has more than 13,800 employees in 59 countries. The company’s 2013 revenue was $3.02 billion, its 38th consecutive year of growth and profitability. Goodnight considers his employees to be his most valuable asset and has created a world-renowned workplace model. In 2013, SAS ranked No. 2 on the World’s Best Multinational Workplaces list from Great Place to Work Institute.

Ms. Mary R. GrealyPresident Healthcare Leadership Council

Mary Grealy is president of the Healthcare Leadership Council, a coalition of chief executives of the nation’s leading health care companies and organizations. The HLC advocates consumer-centered health care reform, emphasizing the value of private sector innovation. It is the only health policy advocacy group that represents all sectors of the health care industry. She was appointed to the position in August 1999.

Ms. Grealy has an extensive background in health care policy. She has led important initiatives on the uninsured, Medicare reform, improving patient safety and quality,

protecting the privacy of patient medical information and reforming the medical liability laws. She testifies frequently before Congress and federal regulatory agencies.

From 1995 until she began her tenure at HLC, she served as Chief Washington Counsel for the American Hospital Association, a national organization representing all types of hospitals, health systems and health care networks. In her position, she was responsible for the organization’s legal advocacy before Congress, as well as executive and judicial branches of government.

From 1979 to 1995, Ms. Grealy was Chief Operating Officer and Executive Counsel for the Federation of American Hospitals, a trade association representing 1,700 investor-owned and managed hospitals and health systems. She coordinated legislative and regulatory policies as well as lobbying activities for the Federation.

Ms. Grealy has a bachelor degree from Michigan State University and a law degree from Duquesne University. She is a member of the Board of Directors of TEAMHealth, one of the largest providers of outsourced

6 7

physician staffing solutions for hospitals in the United States, and the Board of Directors of Duquesne University serving on the Executive Committee. She is a member of the American Health Lawyers Association. She also serves on the advisory boards of the David A. Winston Health Policy Fellowship, Women Business Leaders in Health and the March of Dimes Public Policy Council. She is a frequent public speaker on health issues and has been ranked many times by Modern Healthcare as one of the 100 Most Powerful People in Healthcare and has been named to Modern Healthcare’s list of the Top 25 Women in Healthcare.

Mr. Edward GreissingVice President, North American Corporate Affairs Sanofi

Edward Greissing serves as Vice President, N.A. Corporate Affairs for Sanofi US. Mr. Greissing is responsible for the company’s Chronic Disease Prevention and Wellness Program, Health Innovation, Academic and Scientific Affairs, Federal and State government relations, public policy, reimbursement, global institutional relations, regional and local alliance development, patient advocacy, civic action, and corporate social responsibility.

Prior to joining Sanofi US, he was President and CEO of Red Line Associates, a consulting firm with clients from the biopharmaceutical, device, food service and

financial industries. For the 25 years before he established Red Line, he built a business-focused global government affairs organization for Upjohn which eventually became Pharmacia.

Before entering industry in 1978, Mr. Greissing served as a staff member of the U.S. Senate Intelligence Committee. During his time working with the Committee he contributed to a variety of Committee investigations and final reports. In addition, Mr. Greissing served in the United States Army where he was a member of the honor detail for the 561st Military Police Company stationed at Fort Myer, Virginia. During his service he supported ceremonies honoring our troops and senior dignitaries at Arlington Cemetery.

Mr. Greissing is a graduate of Holy Cross and received his Masters Degree in Congressional Studies and Politics from Catholic University. He and his wife are the parents of seven children and reside in McLean, Virginia.

Dr. Mimi Hancock, PhDPartner Spencer Stuart

Mimi Hancock is a member of Spencer Stuart’s Life Sciences Practice, working out of the San Francisco office. Her search experience has given her the opportunity to complete assignments for organizations ranging from emerging life sciences companies to multinational biotechnology, pharmaceutical and medical technology firms. She has executed searches for board members as well as senior executives in general management, R&D, a variety of commercial, finance and business development positions.

Before entering the executive search industry, Mimi served as vice president of operations and co-founder at Avigen, a startup gene therapy company. For two years prior, she was the director of cell biology at Somatix Therapy Corporation, a publicly held company focused on gene therapy.

8

Earlier in her career, Mimi worked at Triton Biosciences, where she conducted pioneering research on a novel therapeutic approach targeting the Her2 protein in breast and ovarian cancer (Hancock et al; Cancer Research, 1991). Mimi began her career in healthcare with Peralta Cancer Research Institute as a staff scientist.

She is currently a participant in the CEO Roundtable on Cancer and was previously on the board of directors of Bionovo, a public company developing novel therapeutics for breast cancer and women’s health.

Mimi received her B.A. with honors in biological sciences from The University of Chicago and her PhD in genetics from the University of California, Berkeley. She was a postdoctoral fellow at Stanford University and a recipient of a Damon Runyon-Walter Winchell Cancer Fund Fellowship.

Dr. E. Wayne Holden, PhDPresident and CEO RTI International

E. Wayne Holden, PhD, became RTI International’s fourth president and chief executive officer in 2012. Dr. Holden is a distinguished researcher and clinical psychologist with more than 27 years of professional experience. He joined RTI as executive vice president of Social and Statistical Sciences in 2005, overseeing the organization’s largest unit. Prior to joining RTI, he served as vice president, senior vice president and ultimately president of the research company ORC Macro. Before joining ORC Macro in 1998, he had a successful career in academia serving more than 10 years in a variety of roles in the Department of Pediatrics at the University of Maryland’s School of Medicine, including as director of pediatric psychology and as

a tenured associate professor. Since 2006, Dr. Holden has held an appointment as an adjunct professor in the Department of Psychiatry and Behavioral Sciences at Duke University School of Medicine. He is also an adjunct professor in the Department of Health and Policy Management at the University of North Carolina Gillings School of Global Public Health. Dr. Holden is a fellow of the American Psychological Association and has authored more than 130 articles on various topics in clinical child/pediatric psychology and health services research. He currently serves on the Board of Directors for United Way of the Greater Triangle and Ziptronix. He is also on the Board of Advisors for the Emily Krzyzewski Center and the Frank Hawkins Kenan Institute of Private Enterprise, and he is an elected trustee for the Triangle University Center for Advanced Studies, Inc. (TUCASI).

Mr. David HolmbergPresident and CEO Highmark Health

David Holmberg is president and chief executive officer (CEO) of Highmark Health, a diversified health and wellness enterprise based in Pittsburgh, Pa., that serves an estimated 35 million people nationwide. Passionate about solving our nation’s most pressing health care problems, Mr. Holmberg is committed to improving the total health care experience for members, patients and consumers in a rapidly changing health care landscape.

Mr. Holmberg joined Highmark in 2007, serving in a series of executive positions. Most recently he was president, Diversified Businesses for Highmark Inc., where he

8 9

was responsible for businesses representing more than $3.5 billion in revenue. He has also served as chief executive officer for HVHC Inc. and chief executive officer and chairman for HM Insurance Group, United Concordia Dental and San Antonio, Texas-based Visionworks, formerly Eye Care Centers of America (ECCA).

Mr. Holmberg is active in his community and supports several causes including the Warrior and Family Support Center at Brooke Army Medical Center, Children’s Medical Center of Dallas and the United Way. He is a Distinguished Alumni of the University of Texas at Dallas School of Management and a member of the University of Texas at Dallas School of Management Advisory Board.

He received his MBA from the University of Texas at Dallas and is a graduate of the Harvard Business School’s Advanced Management Program.

Dr. Paul Howard, PhDDirector and Senior Fellow, Center for Medical Progress Manhattan Institute for Policy Research-

Dr. Howard is a Manhattan Institute senior fellow and director of the Manhattan Institute’s Center for Medical Progress. He is also a contributor to The Apothecary, the influential Forbes blog on health care policy and entitlement reform, and a regular columnist for The Morning Consult.

He has written on a wide variety of medical policy issues, including FDA reform, biopharmaceutical innovation, consumer-driven health care, Medicare and Medicaid policy, and health care reform. He is often quoted on health care issues and his columns and essays have appeared in national publications, including Bloomberg

View, The Wall Street Journal, National Affairs, USA Today, Real Clear Politics, New York Post, Investor’s Business Daily, Health Affairs, and FoxNews.com.

He is also a member of the Manhattan Institute’s Project FDA, a committee of physician-scientists, economists, medical ethicists, and policy experts. Their purpose is to show how twenty-first-century technologies can help better inform FDA regulations and accelerate the drug-development and drug-approval process while maintaining drug safety.

In 2012, Howard served on the Health Care Policy Advisory Group for the presidential campaign of former Massachusetts governor Mitt Romney. He has also testified twice before Congress. In 2013 and 2014, he served on an expert panel as a judge for Celgene’s Innovation Impact Awards.

Howard joined the Manhattan Institute in 2000, working as deputy director of the Center for Legal Policy where he edited research papers, managed legal policy analyses, and organized conferences.

Howard received his PhD in political science from Fordham University in 2003, and is a graduate of the College of the Holy Cross in Worcester, Massachusetts.

10

Dr. Charles Hugh-Jones, MD, MRCPChief Medical Officer Sanofi

Dr. Hugh-Jones trained in neuroscience at Imperial College, London, UK. He went on to qualify as a physician at Charing Cross and Westminster Medical School. He completed internal medicine Boards while practicing at Chelsea and Westminster Hospital, and St. Mary’s Hospital, London, becoming a Member of the Royal College of Physicians. He then entered the radiology fellowship program at the Royal Postgraduate Medical School, Hammersmith Hospital, London.

He joined Schering AG/Bayer AG in 2001, where he worked in the Oncology Strategic Business Unit based first in the UK and then in New Jersey, USA providing

global medical leadership to several key brands.

Dr. Hugh-Jones subsequently served as Vice President of Medical Affairs at Enzon Pharmaceuticals from 2006 to 2008 and then as Vice President of Global Business Management from 2008 to 2010.

Dr. Hugh-Jones joined Sanofi-Aventis in 2010 as head of U.S. Medical Affairs Oncology. With the integration of Genzyme he headed up Medical Affairs, North America for Sanofi Oncology, Hematology and Solid Organ Transplantation. Separately he was a key architect of the cross-industry and academia not-for-profit ProjectDataSphere.org open-access oncology data sharing platform that launched in 2014.

He was named Chief Medical Officer for Sanofi North America in 2012. In 2014 he was elected a Fellow of the Royal College of Physicians of the UK.

Mr. Robert A. IngramGeneral Partner Hatteras Venture Partners

Bob Ingram joined the firm of Hatteras Venture Partners as a General Partner on January 24, 2007. Hatteras Venture Partners is a venture capital firm that invests in early stage life science companies in the southeast United States.

Bob began his career in the pharmaceutical industry as a professional sales representative and rose through a series of roles with increasing responsibility to ultimately become CEO/Chairman of GlaxoWellcome. He co-led the merger and integration that formed GlaxoSmithKline, the world’s second largest pharmaceutical company. Upon reaching the mandatory retirement age of 60, he was asked by the

Board to serve as Vice Chairman Pharmaceuticals, GSK, which he did until January 1, 2010, at which time he became Strategic Advisor to the Chief Executive Officer, GlaxoSmithKline plc.

He serves as Lead Director of Valeant Pharmaceuticals International and Cree, Inc. He is also a member of the Board of Directors of Edwards Lifesciences Corporation and Regeneron Pharmaceuticals, Inc. and is Chairman of Viamet, a private company focused on anti-infective research.

In addition to his professional responsibilities, Bob was asked by former US President George H.W. Bush to form and chair the CEO Roundtable on Cancer. He is a member of numerous other civic and professional organizations. In January 2004, Bob was awarded the Martin Luther King, Jr. Legacy Award for International

10 11

Service. On July 27, 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board.

Bob is a member of the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and Chairman, GlaxoSmithKline Foundation. He serves as Chairman of Research Triangle Foundation of North Carolina and is on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.

Bob graduated from Eastern Illinois University with a BS degree in Business Administration.

Dr. Fikry W. Isaac, MD, MPH, FACOEMVice President, Global Health Services Johnson & Johnson

Dr. Isaac directs Johnson & Johnson’s development of health and wellness strategies, policies, guidelines, and services worldwide (Occupational Medicine, Employee Assistance Program and Wellness). He is also the Chief Medical Officer for Johnson & Johnson’s Wellness & Prevention, Inc., a company offering comprehensive wellness solutions for employers, health plans and other organizations.

Dr. Isaac is a pioneer in the field of workplace health promotion and global health, and has introduced innovative approaches to improve the health and well-being of

populations. He is a published author in this field and continues to research population health interventions, using rigorous scientific methods, to ensure that these interventions deliver meaningful outcomes. His broad view spans the fields of clinical medicine, behavior change technologies, and economic analyses. Dr. Isaac is an outspoken champion of prevention and health promotion and has successfully gained support and funding from senior management for health improvement initiatives for all Johnson & Johnson employees worldwide.

Dr. Isaac has taken important public policy leadership positions among employer groups and government officials. During health care reform discussions in the US, he was invited to meet with officials of the Office of Personnel Management and the White House to provide input to a pilot program for health and wellness in the federal workforce.

Dr. Marek Kania, MD, MBAVP, Global Medical Affairs and Late Phase Product Development, Oncology Eli Lilly and Company

Dr. Marek Kania, M.D., M.B.A.

Vice President, Global Medical Affairs and Late Phase Product Development, Oncology,Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN

Marek Kania, M.D., M.B.A. joined Eli Lilly and Company in 1993. Before joining Lilly he practiced as an anesthesiologist and critical care physician. In earlier years with Lilly, Dr.Kania championed the creation of Lilly Oncology infrastructure in Africa, Middle East, and Europe. Subsequently, he assumed global leadership roles both on the business side and later in oncology drug development, where he has been instrumental in the development and approval of Lilly Oncology initial product portfolio like Gemzar and Alimta and the research and development of our newer molecules within robust oncology pipeline. After acquisition of Imclone Systems, he led the clinical development of Erbitux across the alliance. In 2012 he was promoted to Vice President, Global Medical Affairs and Late Phase Product Development, Oncology. Dr. Kania is responsible for the global medical organization and late phase product development within Lilly Oncology. Dr. Kania received his medical training at the Silesian School of Medicine in Katowice, Poland and subsequently completed the anesthesiology and critical care residency, with board certification from Jagiellonian School of Medicine in Krakow. Dr. Kania holds an M.B.A. degree from The University of Chicago Booth Graduate School of Business.

Marek Kania, MD, M.B.A. joined Eli Lilly and Company in 1993. Before joining Lilly he practiced as an anesthesiologist and critical care physician. In earlier years with Lilly, Dr. Kania championed the creation of Lilly Oncology infrastructure in Africa, Middle East, and Europe. Subsequently, he assumed global leadership roles both on the business side and later in oncology drug development, where he has been instrumental in the development and approval of Lilly Oncology initial product portfolio like Gemzar and Alimta and the research and development of our newer molecules within robust oncology pipeline. After acquisition of Imclone Systems, he

12

led the clinical development of Erbitux across the alliance. In 2012 he was promoted to Vice President, Global Medical Affairs and Late Phase Product Development, Oncology. Dr. Kania is responsible for the global medical organization and late phase product development within Lilly Oncology. Dr. Kania received his medical training at the Silesian School of Medicine in Katowice, Poland and subsequently completed the anesthesiology and critical care residency, with board certification from Jagiellonian School of Medicine in Krakow. Dr. Kania holds an M.B.A. degree from The University of Chicago Booth Graduate School of Business.

Mr. Thomas KeanPresident and CEO C-Change

Tom Kean has devoted more than 35 years of his career to chronic disease prevention and control. He has served government, not-for-profit and for profit institutions in progressively responsible positions as a health educator, evaluator and senior manager/administrator. His assignments have included the University of Texas System Cancer Center, the National Cancer Institute, and the AMC Cancer Research Center. In 1994, he co-founded Strategic Health Concepts, a Colorado based consulting company, to help health organizations better achieve their goals through sound planning and management combined with solid technical capacity. In 2006, Tom became the President and CEO of C-Change, a coalition of leaders from

organizations representing the public, private and voluntary sectors devoted to eliminating the burden of cancer on the US population. In addition to his professional activities, Tom has been actively involved over the years in volunteer work with community groups for public school education, cancer control and tobacco use prevention. In 1986, he was awarded the NIH Award of Merit for his contributions in cancer prevention and control. In 1993, he received the National Cancer Institute’s Marion Morra Award for his contributions in cancer communications. In 2009, he received the Distinguished Visionary Leader in Medicine award from the Life Beyond Cancer Foundation.

Dr. Stephen Kindred, MDAVP – Medical Director State Farm Insurance

Kindred joined State Farm as an assistant Medical director in 1990, was promoted to Medical director in 1994 and assumed his current position in 1998.

A native of Illinois, Kindred received a bachelor’s degree from Wabash College, Crawfordsville, Ind., and a doctor’s degree from the University of Illinois College of Medicine, Peoria. He served his residency in internal medicine at Mayo Clinic, Rochester, Minn. Kindred received his master of public health degree in May, 2006, from The Medical College of Wisconsin. He is a diplomat of the American Board of Internal Medicine.

Kindred is a member of the American College of Physicians and a member of the American Medical Association, the Illinois State Medical Association, and the McLean County Medical Society.

12 13

Mr. Michael L. KlowdenCEO The Milken Institute

Michael Klowden is CEO of the Milken Institute. During his tenure, the Institute’s annual Global Conference has become one of the world’s premier business, finance and policy events. Under his leadership, the Institute dramatically enhanced its worldwide outreach; significantly increased its convening capacity; initiated specialized research centers, including the Asia Center, the California Center and the Center for Public Health; established a major presence in Washington, D.C., with the founding of FasterCures and the Center for Financial Markets; and expanded the use of Financial Innovations Labs that suggest solutions to specific challenges. Previously Klowden was president of Jefferies Group Inc.; senior partner at Morgan,

Lewis & Bockius; and partner at Mitchell, Silberberg & Knupp. He has served on numerous for-profit and charitable boards. Klowden holds a bachelor’s degree from the University of Chicago, where he is now a trustee, and a J.D. from Harvard Law School.

Coach Mike Krzyzewski (Coach K)Head Coach, Men’s Basketball Duke University Athletics

Army ‘69 • 39 seasons (34 seasons at Duke)983-306 overall • 910-247 at Duke

Winning seasons, superb graduation rates for his players and a basketball team that is as close as family are all attributes that reflect on the man who has spent over three decades as the head coach of the Duke Blue Devils, Hall of Famer Mike Krzyzewski.

Coach K, the winningest coach in NCAA Division I history after passing his mentor Bob Knight with a 74-69 win over Michigan State on Nov. 15, 2011, now has

983 career wins, while also ranking second in wins at one school (910), second in career ACC wins (417) and first in NCAA Tournament victories (82).

Krzyzewski’s involvement with USA Basketball has also made him a prominent figure on the international basketball stage where he has helped Team USA to 14 medals and a 125-7 record throughout his career. As head coach of the USA Men’s Senior National Team, a post he assumed on Oct. 26, 2005, Coach K has led Team USA to a 75-1 record, including an active 63-game win streak, with gold medals at the 2007 FIBA Americas Championship, 2008 Beijing Olympics, 2010 FIBA World Championship, 2012 London Olympics and 2014 FIBA World Cup.

14

Dr. Peter F. Lebowitz, MD, PhDGlobal Therapeutic Area Head, Oncology Janssen R&D

As Global Therapeutic Area Head of Oncology, Dr. Lebowitz has end-to-end responsibility for Oncology Research and Development from discovery through development and life cycle management. He leads a global team focused on combining internal and external innovation approaches to discover and develop new solutions for oncologic and hematologic diseases with high unmet medical need.

Prior to taking on the Therapeutic Area Head role, Dr. Lebowitz was Head of the Hematologic Malignancy Disease Area. In this role, he was responsible for strategic oversight and execution of Janssen’s hematologic malignancy drug discovery and

development programs. Before joining Janssen, Dr. Lebowitz was Vice President in both early and late-stage clinical development for another leading pharmaceutical company, where he successfully filed 10 INDs, played a major role in the global registration of three oncology drugs, and led major projects from preclinical discovery through pivotal Phase 3 trials.

Prior to joining the industry, Dr. Lebowitz was Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, where he established an independently funded translational and clinical research program and was a Principal Investigator on numerous clinical research trials. Dr. Lebowitz graduated from Harvard University and earned his MD and PhD degrees from the University Of Pennsylvania School Of Medicine. He then completed his hematology/oncology fellowship at the National Cancer Institute, National Institutes of Health.

Mr. Kenneth B. Lee, Jr.General Partner Hatteras Venture Partners

Kenneth B. Lee, Jr. is involved in deal sourcing, investment decisions and implementing exit strategies as a general partner of HVP III. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation. Ken is the former co-head of International Life Sciences for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.

He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the firm’s national life sciences practice from his

location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.

Ken serves on the Board of Directors of Clinverse, and is Chairman of the Board of Clinipace. He graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.

14 15

Mr. François MaisonrougeSenior Managing Director Evercore Partners-

François Maisonrouge is a Senior Managing Director in Evercore Partners’ advisory business with 29 years of relevant experience.

At Evercore, Mr. Maisonrouge is currently acting for Shire in its defense against the unsolicited approach by AbbVie; and also acted for AstraZeneca in its defense against the unsolicited proposal by Pfizer. He is involved in advising Sun Pharmaceutical Industries on its pending acquisition of Ranbaxy Laboratories, Aptalis on its sale to Forest Pharmaceuticals, Bristol-Myers Squibb on its acquisition of Amylin and sale of half of its interest in Amylin to AstraZeneca, Fenwal on its sale

to Fresenius, Sage Products on its sale to Madison Dearborn, Terumo on its acquisition of CaridianBCT, Sanofi on its acquisition of Genzyme and of Merck’s 50% stake in Merial, Movetis on its sale to Shire, TPG on its acquisition of IMS Health, and Wyeth on its combination with Pfizer.

Prior to joining Evercore, Mr. Maisonrouge was a Managing Director and Chairman of Life Sciences at Credit Suisse where he worked extensively in the fields of pharmaceuticals, specialty pharmaceuticals, biotechnology and medical technology. At Credit Suisse, Mr. Maisonrouge was responsible for leading the firm’s relationships with large healthcare clients such as Johnson & Johnson, Schering-Plough, Wyeth, GlaxoSmithKline, Roche and Teva, most notably in executing mergers and acquisitions and capital raising transactions.

Mr. Maisonrouge has an M.S. in Engineering from Ecole Centrale de Lyon and an M.B.A. from Harvard Business School. He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the Chairman of the Pasteur Foundation. In 2014, Mr. Maisonrouge was named Chevalier de la Légion d’Honneur.

Dr. Viren Mehta, PharmD, MBAManaging Member Mehta Partners

Viren Mehta founded and is managing member of Mehta Partners, LLC, celebrating its 27th year of providing strategic advice to biopharma leader and to portfolio managers. His wide-ranging perspective and analytical insights on global health care have influenced bio-pharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has recently co-founded and is Executive Chairman of Gather Health, a platform that empowers patients with a team to achieve better outcomes while enhancing physician efficiency and productivity.

Today, Viren focuses on strategic advisory work with two primary interests: refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. Viren’s philanthropic work in ecology and education includes an active board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA).

Viren began with Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function

16

in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, Viren continues to focus on the same mission: helping refine investment strategy to achieve superior growth while enhancing access to efficient healthcare.

Dr. Alan Metz, M.B.B.ChSr. VP and Managing Director - Strategic Partnerships Quintiles Transnational Corp.

Alan Metz, BSc, MBBCh, MRCPsych, Fellow APA obtained his medical degree from the University of Witwatersrand, Johannesburg, South Africa. He is a member of the Royal College of Psychiatrists in London and board certified by the American Board of Psychiatry and Neurology. He received his training in psychiatry and a fellowship in psychopharmacology in Oxford, England and, before moving to Industry, was Assistant Professor at Tufts/New England Medical Center in Boston.

Alan joined Quintiles in 2010 as Senior Vice President and Managing Director for Strategic Partnerships. Prior to joining Quintiles, Alan served in various roles at

GlaxoSmithKline including Global Head of CNS Drug Development, Head of International and US Medical Affairs, Chief Medical Officer for North America and Head of the Office of External Affairs

He has teaching appointments at Duke University as an Associate Consulting Professor of Psychiatry and also at the University of North Carolina at Chapel Hill as a Clinical Associate Professor of Psychiatry.

Mr. Jez MouldingPresident, North America Pharmaceuticals Sanofi

Jez Moulding is President of North America Pharmaceuticals for Sanofi, a global diversified healthcare company. He oversees all pharmaceutical operations within the U.S. and Canada, including Business Development, Commercial Strategy & Operations, Consumer Healthcare (Chattem), General Medicines, Launch Excellence Unit, Market Access, Medical Affairs and Patient Centered Units (Diabetes, Allergy, Cardiovascular & Specialty Care).

Jez serves as a member of Sanofi’s Global Leadership Team, the Global Commercial Operations Committee and the U.S. Regional Strategic Management Committee.

A distinguished and dedicated professional with more than 20 years of experience, Jez began his pharmaceutical career as a Sales Representative with Astra in the United Kingdom and moved onto positions of greater responsibility before joining Sanofi in 1998 as the UK Cardiovascular Marketing Manager. At Sanofi, he held various leadership roles in the UK and European Region, including four General Manager positions in South Africa, Korea, Australia and Japan. Most recently, until October 2014, Jez served as the Senior Vice President of the Japan & Pacific Region, where he was responsible for overseeing business in Sanofi’s second largest market.

Jez holds an MA in Politics, Economic and Social History from Edinburgh University.

16 17

Mr. Robert J. MulroyPresident and CEO Merrimack Pharmaceuticals

Robert J. Mulroy serves as our President and Chief Executive Officer and a member of our board of directors. Prior to joining Merrimack, Mr. Mulroy worked as a management consultant specializing in the healthcare and pharmaceutical industries. Mr. Mulroy also worked as a consultant in the field of international development and has served as an advisor to start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and private management from Yale University and a B.A. from Stanford University.

Dr. Martin J. Murphy, Jr., PhD, DMedScCEO CEO Roundtable on Cancer

Martin J. Murphy, Jr., PhD (New York University), DMedSc (Queen’s University-Belfast, h.c.), FASCO, is Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., that provides strategic support for academic cancer centers and cancer drug development programs of global pharmaceutical and biotechnology companies. Founding Executive Editor of the 18-year-old peer-reviewed journal, The Oncologist (Bruce A. Chabner, editor-in-chief), he is also the Founding Executive Editor of both Stem Cells (Jan Nolta, editor), a 30-year-old journal of stem cell biology, and of the journal, Stem Cells Translational Medicine (Anthony Atala, editor).

Dr. Murphy was founder and former Chief Executive Officer of the Hipple Cancer Research Center, NIH principal investigator and has authored more than 150 peer-reviewed papers. Co-founder of the Society for Translational Oncology (Richard M. Goldberg & Patrick G. Johnston, co-chairs), he is a member of the Scientific Advisory Board (Herbert Boyer, chair) of Hatteras Venture Partners, a charter member of the International Advisory Board of the VU University Medical Imaging Center, a charter member of Queen’s University-Belfast School of Medicine International Review Board, Chairman Emeritus of the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO), convener of ACT-China (Advanced Clinical Trials-China; Shukui QIN & Yi-Long WU, co-chairs), and Steering Committee Member and Senior Consultant of the Chinese Society of Clinical Oncology. A member of the National Cancer Policy Forum (John Mendelsohn, chair) of The Institute of Medicine (IOM) of the United States National Academy of Sciences, he is a director of the Foundation for the National Institutes of Health (Charles Sanders, chair), member of the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center, member of the Board of Advisors of the H. Lee Moffitt Cancer Center & Research Institute (Bob Griese, chair) and is charter member and director of C-Change founded by former President George H. W. Bush and former First Lady Barbara Bush. Dr. Murphy is a Fellow of the American Society of Clinical Oncology (FASCO, 2013); he is Chief Executive Officer of the non-profit CEO Roundtable on Cancer at the request of the Forty-first President George H.W. Bush. Christopher A. Viehbacher is the chairman, William C. Weldon, past-chairman, and Robert A. Ingram is founding chairman of the CEO Roundtable on Cancer.

18

Dr. Ann Murphy, PhDPresident and CEO AlphaMed Press

Ann Murphy, PhD is the publisher and managing editor of three world-class, peer-reviewed journals: The Oncologist, STEM CELLS, and its sister journal, STEM CELLS Translational Medicine.

STEM CELLS is the oldest journal in the fast-paced area of stem cells and regenerative medicine. Ann has managed the Journal during its 32 year history as the pioneering journal in the area of stem cell research. She continues to maintain the Journal’s excellence as it exponentially expands its size and scope as a top-tier global peer-reviewed journal devoted to stem cell biology. STEM CELLS editor-in-chief is Professor Jan Nolta.

STEM CELLS TRANSLATIONAL MEDICINE (SCTM), now in its third volume, is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. Ann as managing editor works closely with its founding editor-in-chief, Professor Anthony Atala.

Ann is also the Founding Managing Editor of The Oncologist journal, a monthly international peer-reviewed journal for physicians devoted to cancer patient care, and has guided and nurtured its growth and development over its nineteen year history. The Oncologist founding editor-in-chief is Professor Bruce A. Chabner. She has also led The Oncologist Continuing Medical Education (CME) Program from its inception and is Board Designate of the Society for Translational Oncology (STO), accredited by the ACCME. STO is co-chaired by Professor Richard Goldberg and Professor Patrick Johnston.

Ann played a salient role when the Senior Editors of The Oncologist® founded STO in 2000 to fill the gap between discovery of new oncology treatments and their global translation into oncology practice. The Oncologist is the official journal of STO.

Ann holds a Doctorate of Philosophy with distinction in Literature from New York University. She serves on the Board of Visitors of the UNC Lineberger Comprehensive Cancer Center. She is a published authority on the Irish Literary Renaissance and the biographer of the Irish playwright and poet, Padraic Colum. A mother of five and grandmother of ten, she makes her home with her husband, Martin J. Murphy, in Durham, North Carolina.

Ms. Judy O’HaganVP U.S. Human Resources Sanofi

Since September 2007 Judy O’Hagan has been a Vice President of Sanofi US, where her scope of responsibilities include North America Pharmaceuticals, Global Services, Consumer Health Care, and R&D. At Sanofi, O’Hagan serves as the Steering Committee Chairperson for WISE (Women Inspiring Sanofi Excellence) and is a member of the 2012 Healthcare Businesswomen’s Association Advisory Board. She also serves as the Co-Chair of the CEO Cancer Gold Standard Task Force for the CEO Roundtable on Cancer. In her community, she serves on the Board of Jersey Battered Women’s Services and as a liaison to the Cristo Rey Network in Newark, New Jersey.

18 19

O’Hagan began her career in the pharmaceutical industry in 1978 as an HR professional at Sandoz Pharmaceuticals Corporation, and in 1996, when Sandoz and Ciba-Geigy merged to form Novartis Pharmaceuticals, she was appointed Executive Director for the Organization and Leadership Development function. In 1999, she was appointed Vice President, Human Resources for the Commercial Division of Novartis.

Mr. Paris PanayiotopoulosPresident and Managing Director EMD Serono, Inc.

EMD Serono, Inc. is a subsidiary of Merck KGaA, Darmstadt, Germany

Senior Leadership

April 2014

Paris Panayiotopoulos is the President and Managing Director of EMD Serono, Inc. In this capacity, his responsibilities include driving the strategic direction of the US organization, as well as managing the operations of the US subsidiary of Merck KGaA, Darmstadt, Germany.

Mr. Panayiotopoulos is a strong, people-oriented leader, who cultivates a deep sense of customer urgency within the organization with a focus on achieving scientific leadership in the areas of multiple sclerosis and fertility, and growing the US business as a top specialty care company.

Mr. Panayiotopoulos comes to EMD Serono from the company’s Japan affiliate, Merck Serono, where he served as President and Managing Director. In this role, he demonstrated his leadership in driving cultural and organizational change, including the management of many alliances to achieve strong growth.

Mr. Panayiotopoulos joined Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2004, and has since held positions of increasing responsibility across multiple franchises and regions, including Head of Western Europe Operations, Director of Global Marketing, Global Commercial Team Leader, and Head of the COO Office.

Prior to joining Merck Serono, Mr. Panayiotopoulos gained experience across multiple global brands at Eli Lilly & Company, based in the UK.

Paris PanayiotopoulosPresident and Managing Director of EMD Serono, Inc.

Paris Panayiotopoulos is the President and Managing Director of EMD Serono, Inc. In this capacity, his responsibilities include driving the strategic direction of the US organization, as well as managing the operations of the US subsidiary of Merck KGaA, Darmstadt, Germany.

Mr. Panayiotopoulos is a strong, people-oriented leader, who cultivates a deep sense of customer urgency within the organization with a focus on achieving scientific leadership in the areas of multiple sclerosis and fertility, and growing the US business as a top specialty care company.

Mr. Panayiotopoulos comes to EMD Serono from the company’s Japan affiliate, Merck Serono, where he served as President and Managing Director. In this role, he demonstrated his leadership in driving cultural and organizational change, including the management of many alliances to achieve strong growth.

Mr. Panayiotopoulos joined Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2004, and has since held positions of increasing responsibility across multiple franchises and regions, including Head of Western Europe Operations, Director of Global Marketing, Global Commercial Team Leader, and Head of the COO Office.

Prior to joining Merck Serono, Mr. Panayiotopoulos gained experience across multiple global brands at Eli Lilly & Company, based in the UK.

Mr. J. Michael PearsonChairman and CEO Valeant Pharmaceuticals

Mr. Thomas PikeCEO Quintiles Transnational Corp.

Tom Pike is Chief Executive Officer of Quintiles and serves on its Board of Directors. In this role, Tom is responsible for driving the company’s growth as the world’s leading provider of biopharmaceutical services. Quintiles delivers services and information that enable its customers to evaluate and demonstrate the safety, efficacy and value of products over the course of their lifecycle. Tom spends much of his time with customers, learning more about the challenges they face and helping them to navigate the complex healthcare environment with greater productivity and predictability. A Fortune 500 company with more than 30,000 employees in 100 countries, Quintiles’ global headquarters is located in Durham, North Carolina.

20

Tom has concentrated his career in the healthcare and technology industries and he is viewed as a leading expert in the provision of business services within these fields. With 30 years of experience, Tom brings an integrated, patient-centric view of healthcare, spanning pharma, payers, and providers to help customers be successful.

Mr. Philip D. Porter, J.D., M.EdOf Counsel Hogan Lovells US LLP

Philip Porter is Of Counsel at the law firm of Hogan Lovells. He has assisted the CEO Roundtable on Cancer’s Life Sciences Consortium with preparation of the START Clauses, whose purpose is to accelerate completion of clinical trial agreements, and he has assisted Project Data Sphere, LLC with formulation of its Data Sharing Agreement and Online Service User Agreement and with structuring the LLC’s operations consistent with laws applicable to web-based services.

Dr. Chandra Ramanathan, PhD, MBAHead, Early Pipeline Oncology – Global Marketing Bayer HealthCare

Chandra Ramanathan is the Head of Early Pipeline Oncology Marketing at Bayer HealthCare. In his current leadership role, he is responsible for driving pipeline and portfolio value by developing commercialization strategies to ensure launch success with optimal market access. He is the co-chair of the Value Strategy Team to ensure customer insights (physicians, payer and patients) are incorporated as part of development strategies. He is also responsible for developing the commercial foundation for companion diagnostics development.

Chandra has worked across the pharmaceutical product development and commercialization spectrum for more than 18 years. He has broad commercial and research backgrounds with an M.B.A from the Columbia Business School, PhD in Genomics/Bioinformatics and B.S. in Pharmacy.

Dr. David M. Reese, MDVice President Translational Sciences Therapeutic Area Head, Oncology Global Development Amgen

Dr. David Reese is vice president of Translational Sciences and therapeutic area head for Oncology Global Development. As a member of the Research and Development senior leadership team, he is responsible for Medical Sciences (including Early Development programs across therapeutic areas and biomarker discovery and development), Comparative Biology and Safety Sciences, Pharmacokinetics and Drug Metabolism, and Oncology Global Development. Reese joined Amgen in 2005 and, prior to assuming his current positions, served in various roles in Global Development and Medical Sciences.

20 21

Reese was educated at Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine, and subsequently served on the faculty at UCLA and the University of California, San Francisco. He later was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and chief medical officer of Translational Research International (TORI), a not-for-profit academic clinical research organization. As an oncologist with an extensive background in clinical trial design, methodology, and translational medicine, Reese has published extensively in the fields of clinical research and translational medicine. He is a guest lecturer at the UCLA School of Medicine.

Dr. Mace Rothenberg, MDSr. VP, Clinical Development and Medical Affairs and Chief Medical Officer Pfizer, Oncology

Mace L. Rothenberg, MD, oversees clinical research and development activities as well as post-marketing evaluation and monitoring for all oncology products at Pfizer. Dr. Rothenberg came to Pfizer in 2008 after more than 20 years in academia where he focused on early-stage drug development, clinical trial design, and the coordinated laboratory-clinical evaluation of new therapies for gastrointestinal cancers.

Dr. Rothenberg is the recipient of the American Cancer Society’s Lane W. Adams Quality of Life Award, honoring him as one of the nation’s top cancer caregivers. He also received the American Society of Clinical Oncology’s Statesman Award, honoring

him for more than 20 years of service to the organization, the specialty of oncology and cancer patients. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology.

Dr. Rothenberg received his BA magna cum laude from the University of Pennsylvania in 1978 and his MD from the New York University School of Medicine in 1982. He received his postgraduate training in Internal Medicine at Vanderbilt University from 1982 to 1985 and in Medical Oncology at the National Cancer Institute from 1985 to 1988.

Dr. Charles A. Sanders, MDExecutive Chairman Foundation for the National Institute of Health (FNIH) Retired Chairman and CEO Glaxo

Dr. Sanders is retired from Glaxo, Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. Prior to joining Glaxo, Inc., Dr. Sanders spent eight years with Squibb Corporation, where he held a number of positions, including Vice Chairman. Previously, Dr. Sanders was General Director of Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. Dr. Sanders is currently a member of the Institute of Medicine of the National Academy of Sciences, Chairman Emeritus of Project HOPE and Chairman of the Foundation for the National Institutes of Health.

He is also past Chairman of the UNC Health Care System. Additionally, he serves on the boards of several publicly traded companies. He earned his MD from the University of Texas Southwestern Medical School.

22

Mr. Josh SchaferVP, Global Head Oncology Astellas Pharmaceutical, Inc.

Joshua Schafer is Vice President, Global Oncology Strategy at Astellas Pharmaceuticals, which a global top 20 pharmaceutical company. He has worked in the healthcare industry for nearly 20 years in a variety of capacities including executive management, consulting and entrepreneurship. In his current role Mr. Schafer is responsible for driving global strategy for Astellas Pharmaceuticals’ oncology portfolio. He is a member of the Oncology Leadership team responsible for overseeing the clinical, regulatory and commercial aspects of oncology product development. He was instrumental in the company’s recent $4B acquisition of OSI Pharmaceuticals, as well as the in-licensing and commercialization of several new products. He is pleased to

have been a part of bringing several new products to patients suffering from cancers.

Previously, Mr. Schafer was at Takeda Pharmaceuticals where he held a variety of global roles including New Product Development, Business Development and Marketing. Most recently Mr. Schafer was responsible for New Product Marketing, where he was responsible for providing commercial leadership for Takeda’s oncology and nephrology pipeline, and served in a pivotal role in the $9B acquisition of Millennium Pharmaceuticals. Mr. Schafer held senior positions in global medical affairs, business development, and operations for several bioscience and pharmaceutical companies including Searle (now Pfizer), and Cognia, a bioinformatics startup company, which was acquired. He started his career in management consulting, with Andersen Consulting (now Accenture).

Mr. Schafer holds a MSc and an MBA from Northwestern University and received his undergraduate degree from the University of Notre Dame. He was named one of Crain’s Chicago Business 40 under 40 for 2010. Mr. Schafer is active in the Chicago business community and is a member of Chicago Innovation Mentors, a joint program between Northwestern University, University of Chicago and University of Illinois to stimulate innovation in Chicago area.

Dr. Howard Scher, MDChief, Genitourinary Oncology Service Memorial Sloan Kettering Cancer Center

Howard Scher is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center, Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher has helped elucidate key molecular and genetic features of prostate cancer and translated these insights as leading early and phase 3 registration trials of abiraterone acetate and enzalutamide which are now FDA approved. His research is focused on the validation of circulating tumor cell and other blood based biomarkers to guide the selection of treatment for the individual patient and accelerate drug approvals. Dr. Scher led the international Prostate Cancer Clinical Trials Working Group effort yo

standardize the design and analysis of phase II trials, and serves as the principal investigator of an NIH-supported Specialized Program of Research Excellence in Prostate Cancer and Department of Defense Transformative Impact Award: Toward the Practice of Precision Medicine – A Biomarker Validation Coordinating Center, and is the leader of the Prostate Cancer Clinical Trials Consortium charged with bringing needed drugs to patients faster.

22 23

Mr. David S. SimmonsChairman and CEO PPD, Inc.

David Simmons joined Pharmaceutical Product Development, LLC (PPD) in June 2012 to serve as Chairman and CEO. In this role, he establishes the strategic direction of PPD and leads its global workforce of more than 13,000 employees, across 50 countries, in the design, implementation and execution of drug discovery and development programs on behalf of its biopharmaceutical clients.

A proven leader, Simmons came to PPD following 15 years with Pfizer Inc. In his most recent position, he was President and General Manager of the Emerging Markets and Established Products business units.

Previously, Simmons served as Regional President for Pfizer’s Eastern Europe pharmaceutical division; President of its pharmaceutical division in Greece; and Vice President of Marketing in Canada.

Simmons began his career as a software engineer in the steel industry, where he spent 10 years advancing his career to management positions before transitioning to pharmaceuticals.

He earned a bachelor’s degree in applied mathematics and industrial management from Carnegie-Mellon University.

Simmons also serves as a Director of Owens & Minor, Inc. (OMI). Owens & Minor, a Fortune 500 company, provides distribution and other supply-chain management services to healthcare providers and suppliers of medical and surgical products. He is a Trustee of the Linsly School in Wheeling, WV.

Dr. Michael C. Sokol, MD, MSVP, Employee Wellness Sanofi

Dr. Mike Sokol serves as Vice President, Employee Wellness for Sanofi, a leading global health care and pharmaceutical company. In this role, Dr. Sokol is responsible for designing, implementing, and measuring a fully integrated health and wellness strategy for the employee population and their families. The goal is to create a culture of health by promoting a healthy work environment and providing employees with the tools and resources they need to manage their health along the entire health care continuum.

Most recently, Dr. Sokol served as the Global Corporate Medical Director at Merck, where he was responsible for leading the employee health clinics, occupational health activities, and disability management programs. In addition, he developed the company’s first comprehensive incentives-based health and wellness initiative.

Prior to Merck, Dr. Sokol held positions at Medco Health Solutions and GlaxoSmithKline. In both roles, he provided consultative support to large employers and health plans, focusing on population health and disease management, quality improvement, and value-based insurance design. He also conducted health services and outcomes research demonstrating the clinical and financial benefits of improving medication adherence.

24

Dr. Sokol received his undergraduate degree from Ursinus College in Collegeville, PA and his medical degree from Jefferson Medical College in Philadelphia, PA. He completed his residency in preventive medicine at the University of Maryland Medical System, where he also received his Master of Science degree from the Department of Epidemiology and Preventive Medicine.

Dr. Sokol is board-certified in Public Health and General Preventive Medicine and is a Fellow of the American College of Preventive Medicine. He also holds an academic appointment in the Department of Preventive Medicine at the Mount Sinai School of Medicine in New York.

Dr. Sokol sits on several institute boards at the National Business Group on Health. He serves on the editorial board of the journal Population Health Management and has published several original manuscripts in peer-reviewed medical journals.

Dr. Jeffrey A. Spaeder, MDChief Medical and Scientific Officer Quintiles

Jeffrey A. Spaeder, MD, is Chief Medical and Scientific Officer for Quintiles, the world’s leading biopharmaceutical services company. In this role, Dr. Spaeder serves as Quintiles’ lead medical expert, representing the company’s position on a wide variety of governance, ethical and scientific issues. He chairs Quintiles’ Drug Safety Committee, serves as vice-chair of Quintiles’ Council on Research Ethics, and provides guidance on strategic scientific initiatives.

Prior to joining Quintiles, Dr. Spaeder served in increasingly senior roles within the biopharmaceutical industry at Takeda and Abbott Laboratories and was previously

a cardiologist at Johns Hopkins Hospital. His has performed research in personalized medicine and novel uses of telemedicine, and holds U.S. patents for medical applications of advanced technologies, telemedicine and information systems.

Dr. Spaeder is a graduate of the Pennsylvania State University and the Johns Hopkins University School of Medicine. He also holds a master of business administration (MBA) degree from Northwestern University with a concentration in finance. He is a Fellow of the American College of Cardiology and a Diplomate in cardiovascular disease with the American Board of Internal Medicine.

Ms. Gail StephensSenior Director Health and Life Sciences R&D SAS Institute

Leading collaborative teams that deliver quality software has been Gail Stephens’ mission for more than 28 years at SAS. By combining two of her greatest passions – the advancement of science and world-class SAS analytics – she helps customers harness data’s hidden intelligence to make the world a better place.

She is the executive champion of Health and Life Sciences at SAS, and in this capacity she manages R&D organizations, consults with customers on data-driven initiatives, and evangelizes how SAS software can deliver insights that transform organizations. One of her principal projects is the groundbreaking collaboration

24 25

Project Data Sphere, which is a first of its kind platform that makes historical data and analytics broadly accessible to those seeking to advance cancer treatment research. The project integrates SAS Health and Life Sciences and Business Intelligence (BI) software.

Prior to leading SAS’ Health and Life Science initiatives, she developed graphical user interfaces (GUIs) and managed teams that developed some of the earliest GUIs at SAS. She also spent many years leading the overall BI R&D efforts at SAS, an experience that provided unique insights into streamlining BI software within the Health and Life Sciences projects she oversees today.

Stephens is a North Carolina native and holds a bachelor’s degree in computer science from North Carolina State University in Raleigh, where she has served on the Strategic Advisory Board for the computer science department.

Dr. Bruno Strigini, MS, PhD, MBAPresident, Oncology Novartis

Bruno Strigini is President of Novartis Oncology, a pharmaceutical business unit of Novartis supported by more than 9,000 employees in 85 countries with nine key marketed products and one of the leading pipelines in the industry.

Before joining Novartis in 2014, he was President of MSD for Europe & Canada (Merck & Co., Inc. in the United States and Canada). Previous roles at Schering-Plough, UCB-Celltech and SmithKline Beecham have included President of International Operations, President of Japan and Asia-Pacific, and Head of Global Marketing & Business Development, as well as other senior leadership positions.

Bruno holds an MBA from IMD, Lausanne (Switzerland), a doctorate of pharmacy from the University of Montpellier (France), and a master’s degree in microbiology from Heriot-Watt University (UK). He is a member of the “Académie Nationale de Pharmacie” in France. In 2014, he was awarded Doctor Honoris Causa from Menéndez Pelayo International University (Spain).

Ms. Elizabeth ThompsonCEO Elect C-Change

Ms. Thompson has spent nearly 20 years leading and passionately advocating for the most pressing issues facing our community. She led efforts to establish two organizations, the Dr. Susan Love Breast Cancer Research Foundation, and the Colorectal Cancer Coalition, both of which focused on expanding their research portfolios and utilizing patient advocacy to coalesce around a national agenda. She made tremendous impact on the nation’s investment in pancreatic cancer by establishing the National Action Plan on Pancreatic Cancer while serving at the Pancreatic Cancer Action Network. As President of Susan G. Komen for the Cure, Thompson was responsible for setting strategy and execution of the organization’s

$450M investment in mission programs spanning research, advocacy and policy, community health and education, and global health. Most recently, she was engaged as a transitional CEO to work with the Board,

26

staff and volunteers to re-think and re-energize the Lymphoma Research Foundation, evolving their grassroots base and developing a more dynamic and integrated program offering. Thompson earned her Bachelor of Science degree from the University of South Dakota where she attended the Tom Brokaw School of Communications.

Mr. Timothy TysonChairman Aptuit

Timothy Tyson is currently Chairman of Aptuit LLC, headquartered in Greenwich, CT. His corporate career spans over 30 years in the pharmaceutical industry. His expertise in leadership and management is internationally recognized. From 2002-2008, Mr. Tyson served as COO, President and CEO of Valeant Pharmaceuticals International. During this period, sales grew 69% and earnings increased 135%. He led a major restructuring of the company and established a highly effective Research and Development capability which developed a best in class epilepsy compound, Potiga, which was approved in 2010, and a promising pro-drug for hepatitis C.

Prior to joining Valeant, Mr. Tyson ran multiple divisions for GlaxoSmithKline and was a member of the Corporate Executive Team. During his 14-year tenure at GlaxoSmithKline, he was President, Global Manufacturing and Supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. Mr. Tyson was also responsible for managing all sales and marketing for GlaxoWellcome’s U.S. operations, where he launched 32 new products, eight of which reached sales of greater than $1 billion/year. Mr. Tyson held executive positions in technical operations and R & D, at Bristol-Myers from 1980-1988. Prior to his tenure at Bristol-Myers, he was a manufacturing manager at Procter & Gamble. He served on active duty as an officer in the United States Army from 1974-1979 and spent 14 years in the United States Army Reserves.

Mr. Tyson is a 1974 graduate of the United States Military Academy at West Point. While on active duty at Ft. McClellan, AL, he earned a Master of Public Administration, in 1976, and a Master of Business Administration, in 1979, from Jacksonville State University. In 2002, Mr. Tyson received a Bicentennial Leadership Award from the United States Military Academy at West Point and was named 2007 Alumnus of the Year at Jacksonville State University.

He has served on the board of directors for Valeant Pharmaceuticals International; the Pharmaceutical Research and Manufacturing Association (PhRMA); BICOM; on the CEO Roundtable for the University of California at Irvine; on the Dean’s Executive Forum at Cal State Fullerton; the CEO Roundtable on Cancer; the Health Sector Advisory Board at Duke University; the International Leadership Forum of the International Society of Pharmaceutical Engineers and as a visiting lecturer at Cambridge University. Mr. Tyson has served on the board of directors for non-profit organizations in Raleigh-Durham, NC and Orange County, CA and with the United Way. He currently serves on the Boards of XRPro, Marken, Creeris and TLDG.

26 27

Ms. Ann VickeryOf Counsel Hogan Lovells US LLP

Ann Vickery is Of Counsel in Hogan Lovells’ Washington, D.C. office. Before retiring from the partnership at the end of 2012, she was active in the firm’s health practice, which she led as practice director from 1991 to 2010. She has represented manufacturers, associations, and providers of various healthcare products and services with respect to a wide range of health regulatory issues. She continues to counsel clients occasionally regarding the impact of federal laws, regulations, and policies on their businesses, with a particular emphasis on Medicare and Medicaid. Ann has also been active in the firm’s management, serving two 3-year terms on the Executive Committee of Hogan and Hartson and as Managing Partner of its Washington office.

Over the years, Ann frequently advised clients about emerging trends in health care policy, including efforts to reform the U.S. healthcare system. She was involved in the enactment of the Medicare hospice benefit in 1982 and continues to have a special interest in end-of-life care. Another area in which she has developed considerable experience involves the regulatory processes for integrating innovative new treatments into Medicare and Medicaid coverage and reimbursement policies.

Before joining Hogan & Hartson in 1978, Ann served for a number of years in the executive branch of the federal government. From 1975 to 1978, she worked on the staff of the U.S. Secretary of the Treasury, and from 1969 to 1974, she was a researcher and staff assistant on the White House staff.

Mr. Christopher A. ViehbacherChairman, CEO Roundtable on Cancer President of the EFPIA, European Federation of Pharmaceutical Industries and Associations

Christopher started his career in finance at PriceWaterhouseCoopers and joined GlaxoSmithKline (GSK) in 1988. Throughout the next 20 years with the company, he acquired broad international experience in Europe, in the United States and in Canada. Before joining Sanofi he was President, Pharmaceutical Operations North America. He was also a member of the board and Co‐Chairman of the Portfolio Management Board. Christopher is President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) since June 2013 for a two year term.

Christopher was Chairman of PhRMA in the United States (December 2010 – April 2012) and since February 2011 is Chair of the CEO Roundtable on Cancer. This association brings together employers across the United States to develop and implement workplace initiatives that reduce the risk of cancer, enable early diagnosis, facilitate better access to best available treatments and hasten the discovery of novel and more effective diagnostic tools and anti‐cancer therapies. Over 170 organizations are now members, covering 4.5 million employees.

In 2003, the French government acknowledged his commitment to public health and business by awarding Christopher a knight of the French Legion of Honor. He received the prestigious 2012 Pasteur Foundation Award, recognizing his leadership role within the pharmaceutical industry’s support of research & development and improving health of the 7 billion people around the world. Amongst other commitments, Christopher is also a member of International Business Council (WEF) and a member of the Board of Visitors of Fuqua School of Business, Duke University.

28

Ms. Anne C. WhitakerPresident and CEO Synta Pharmaceuticals

Ms. Whitaker joined Synta as President and Chief Executive Officer and as a member of the Company’s Board of Directors in September 2014. Prior to joining Synta, Ms. Whitaker served as President, North America Pharmaceuticals at Sanofi Aventis US LLC, a global integrated healthcare leader focused on patients’ needs, where she led more than 5,000 employees in generating more than $10 billion in net sales for Sanofi. From 2001 to 2011, she managed all operations within the region including, Business Development, Strategy and Planning/Commercial Operations, Chattem (Consumer Healthcare), Canada Pharmaceuticals, General Medicines, Launch Excellence Unit, Market Access, Meeting Planning, Medical Affairs and Patient

Centered Units (PCU). Anne served as a member of the Global Leadership Team and the US Regional Strategic Management Committee.

A distinguished and dedicated professional with more than 20 years of experience, Ms. Whitaker began her pharmaceutical career at the Upjohn Company in 1991 as a metabolic disease specialist. She joined GlaxoSmithKline in 1992 as a sales representative and held various leadership positions in the commercial organization. In 2007, she became Vice President of Critical and Supportive Care before being appointed Senior Vice President of Leadership and Organization Development from 2008 to 2009. In 2009, Ms. Whitaker became Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology (CVMU) at GlaxoSmithKline where she had full commercial responsibility for leading, developing and managing strategic performance of the CVMU business.

Ms. Whitaker holds a bachelor’s degree in Chemistry with a minor in Business Administration from the University of North Alabama.

Dr. Tal Z. Zaks, MD, PhDSr. Vice President, Head, Global Oncology Division Sanofi

Tal Zaks is Senior Vice President and Head of the Global Oncology Division. Tal is responsible for all global aspects of discovery, development and commercialization of oncology products.

Tal joined Sanofi in May 2010 as the VP of Oncology Development at Sanofi in Cambridge, MA with responsibility for leading the development of compounds through regulatory registration.

Prior to joining Sanofi, Tal led the oncology clinical research team at Cephalon in Malvern, PA., and was at GSK prior to Cephalon.

Tal received his MD/PhD degree from the Ben Gurion University in Israel, and came to the US to conduct post-graduate research in tumor immunology at the NCI with Steven Rosenberg, MD, PhD At the NCI Tal led the evaluation of a novel peptide immunotherapy trial targeting HER2/neu, and conducted research on the role of apoptosis in melanoma immunotherapy.

28 29

Tal completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in Medical Oncology at the University of Pennsylvania. His research at the University of Pennsylvania focused on the genetics of pancreatic cancer and melanoma.

Tal holds the title of an adjunct Associate Professor of Medicine at the University of Pennsylvania, and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers.

Ms. Névine ZariffaVP for Biometrics and Information Sciences AstraZeneca Pharmaceuticals

Névine was born in Cairo, Egypt and was raised in Montréal, Canada. After her training at McGill University and at the University of Waterloo (Mathematics and Statistics), she began her career as a statistician supporting agricultural research before moving to Philadelphia to join SmithKline Beecham in 1991, which went on to become GlaxoSmithKline. She joined AstraZeneca in November 2011 and is currently VP and Head of Biometrics and Information Sciences in Global Medicine Development.

Over the last 20 years, Névine has amassed a wealth of experience in her specialist area and also in driving strategic programs. She has supported early & late-stage clinical

development and marketed products - primarily in the area of Cardiovascular and Metabolism - and has led global teams of quantitative experts across many quantitative disciplines. Névine has also led, or played an integral part in numerous strategic initiatives, working with company colleagues, medical associations, academics and other groups (both PhRMA and FDA-sponsored) to enhance the value of quantitative sciences beyond the traditional role of designing, analyzing and interpreting clinical trials. Névine has been a statistical Reviewer for The Lancet and is the (co-)author of over 25 publications in peer reviewed biostatistics and medical journals.

She is happily married and splits her time between Gaithersburg Maryland and Philadelphia.

Mr. Helmut ZodlVice President & CFO Worldwide Enterprise Business Group & Americas Group Lenovo

Since Spring 2014 Helmut is the CFO of Lenovo’s Worldwide Enterprise business and is in the process of closing the IBM / X86 acquisition creating a world class enterprise business and bringing on board more than 6000 new employees to Lenovo. Helmut is also responsible for managing the CFO agenda for Lenovo’s Americas Group for all product segments. During summer 2014 he moved with his family from Hong Kong to the US.

From 2012 to 2014 Helmut was the CFO for the Asia Pacific region with end to end I&E and business ownership for all the Lenovo business in Asia. During this time Asia Pacific has achieved the number 1 market share position in the Asia PC business and achieved

significant profitability improvements.

30

Prior to his Asia engagement Helmut has been Lenovo’s Global Corporate Controller. During that time he had been tasked in driving Lenovo’s Financial Performance management system on a daily basis. Helmut’s teams also manage the E2E financial processes for all Cost and Expense spending globally in Lenovo. Over the past years Helmut was leading a number of strategic M&A projects that significantly increased Lenovo’s market share position and E2E capabilities in some of the top markets worldwide (Japan, Germany, Brazil, USA).

Prior to Lenovo, Helmut spent several years serving in different roles at PWC as an Auditor and Advisor. After that he spent 6 years with IBM in progressive roles in Accounting, Payroll, Taxes as well as Business Transformation and Channel Finance.

Helmut received his master’s degrees in computer sciences as well as economics from University of Vienna / Technical University of Vienna. He is a Certified Information Systems Auditor.

Helmut is married and has two children, currently living in the US with prior assignments in France, US and Hong Kong.

30 31

CEO Roundtable on Cancer Staff

Mr. John N. DornanExecutive Director CEO Roundtable on Cancer

John N. Dornan, Jr. is the Executive Director of the CEO Roundtable on Cancer, a non-profit organization of CEOs dedicated to eliminating cancer as a public health threat. Dornan provides administrative oversight to the group’s initiatives including the CEO Cancer Gold Standard workplace accreditation program which recognizes employers who provide state-of-the-art preventive care, wellness support and cancer treatment; and the Life Sciences Consortium, which encourages researchers to work collaboratively to accelerate the discovery and development of new therapies for cancer patients. As Executive Director, he reports to CEO Roundtable Chief

Executive Officer, Dr. Martin J. Murphy, Jr.

Dornan formerly headed corporate public reactions for SAS Institute, the world’s largest privately held software company. Prior to joining the CEO Roundtable on Cancer, he served as Vice President of Trone, a mid-Atlantic regional advertising and public relations agency, where he specialized in communications related to corporate mergers and acquisitions. He also held marketing and communications positions with Healthsource North Carolina prior to its acquisition by CIGNA and served as campaign press secretary for former U.S. Congressman H. Martin Lancaster. He began his career in North Carolina’s Department of Health and Human Services where he provided outreach and communications services for the state’s welfare reform efforts and programs for children and families including the nationally renowned Smart Start early childhood initiative created by Gov. James B. Hunt.

Ms. Therese M. MartinProject Manager CEO Roundtable on Cancer

Therese Martin serves as Project Manager for the CEO Roundtable on Cancer a non-profit organization comprised of CEOs dedicated to eliminating cancer as a public health threat. Responsibilities include providing assistance to employers interested in adopting the CEO Cancer Gold Standard, a workplace wellness initiative, managing program data and communications, and providing general support to CEO Roundtable on Cancer initiatives.

Prior to joining the CEO Roundtable in 2011, Martin worked as a project manager in a wide range of industries including military, software, retail, and non-profit. She is

a graduate of the United States Air Force Academy, and earned her MBA in contracts and acquisition from Western New England College.

32

Project Data Sphere, LLC Staff

Dr. Kald Abdallah, MD, PhDChief Project Data Sphere Officer Project Data Sphere, LLC

Kald Abdallah, MD, PhD is the Chief Project Data Sphere Officer and is charged with the development and expansion of the Project Data Sphere® initiative. Project Data Sphere, LLC, is an independent initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium.

Kald has most recently served as Vice President of North America for Medical Affairs at Sanofi, where he also volunteered to help lead key activities of the Project Data Sphere initiative. Kald’s efforts aided AstraZeneca, Bayer, Celgene, Johnson & Johnson, Memorial Sloan Kettering Cancer Center, Pfizer, and Sanofi to become the

pioneering partners in making clinical trial data available via the Project Data Sphere database.

Kald has served in executive oncology R&D roles in the pharmaceutical industry and in academic research settings for the past thirteen years. He joined Sanofi in 2011, having previously held positions in Bristol Myers Squibb and Sao Paulo University Medical School where he was devoted to cancer chemo- and immunotherapy drug development, most notably leading BMS’s global medical team in the development and launch of Ipilimumab (an immunotherapeutic drug selected by SCIENCE Magazine as Breakthrough of the Year – 2013). At Sao Paulo University Medical School, he held teaching and research positions for 5 years before joining the pharmaceutical industry in 2005. Kald earned his MD and PhD degrees from Sao Paulo University Medical School and then matriculated at Harvard Medical School for his postdoctoral fellowship.